Men's health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27797706)

Published in Am J Clin Nutr on October 26, 2016

Authors

Nicholas G Zaorsky1, Thomas M Churilla2, Karen Ruth3, Shelly B Hayes2, Mark L Sobczak2, Mark A Hallman2, Marc C Smaldone4, David Yt Chen4, Eric M Horwitz2

Author Affiliations

1: Department of Radiation Oncology, nicholaszaorsky@gmail.com.
2: Department of Radiation Oncology.
3: Biostatistics and Bioinformatics Facility, and.
4: Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Articles cited by this

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Multiple significance tests: the Bonferroni method. BMJ (1995) 23.46

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA (1996) 10.02

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol (2004) 6.90

Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 6.15

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69

Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (1998) 4.72

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA (1998) 4.19

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int (2003) 3.11

Dietary supplement use among U.S. adults has increased since NHANES III (1988-1994). NCHS Data Brief (2011) 2.82

Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol (2005) 2.79

Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40

The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol (2014) 2.26

Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol (2008) 2.15

Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc (2003) 2.11

The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98

Adverse events associated with dietary supplements: an observational study. Lancet (2003) 1.97

Acute selenium toxicity associated with a dietary supplement. Arch Intern Med (2010) 1.78

Review of liver injury associated with dietary supplements. Liver Int (2011) 1.64

Attitudes and use of complementary medicine in men with prostate cancer. J Urol (2002) 1.02

Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol (2003) 1.01

Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol (2009) 0.98

Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab (Lond) (2014) 0.98

Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. BJU Int (2003) 0.95

Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev (2013) 0.92

What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol (2015) 0.92

The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol (2013) 0.88

Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol (2013) 0.87

Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84

The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat Rev Urol (2012) 0.84

Selenium toxicity from a misformulated dietary supplement, adverse health effects, and the temporal response in the nail biologic monitor. Nutrients (2013) 0.81

Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int (2015) 0.81

Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer (2015) 0.80

Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. Br J Nutr (2015) 0.78

Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev (2016) 0.77

The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol (2016) 0.77

Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. Am J Clin Oncol (2016) 0.77